Medication-info.com Search Menu

Tazverik: Uses, Side Effects and Dosage

Status:
Prescription (Rx) Being discontinued since March 27, 2026 Facts
Strength:
200 mg
Active ingredient:

Patient information: uses, side effects, how to take - Tazverik

What is the most important information I should know about TAZVERIK?

TAZVERIK can cause serious side effects, including:

  • Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

See " What are the possible side effects of TAZVERIK " for more information about side effects.

What is TAZVERIK?

TAZVERIK is a prescription medicine used to treat:

  • adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.
  • adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, and who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you.
  • adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.

    • Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.
    • Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.
  • are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

How should I take TAZVERIK?

  • Take TAZVERIK exactly as your healthcare provider tells you.
  • Take TAZVERIK 2 times each day.
  • Take TAZVERIK with or without food.

  • Swallow TAZVERIK tablets whole. Do not cut, crush, or chew tablets.
  • If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time.
  • Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with TAZVERIK if you get certain side effects.

What should I avoid while taking TAZVERIK?

  • Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
  • Avoid taking St. John's wort during treatment with TAZVERIK.

What are the possible side effects of TAZVERIK?

TAZVERIK can cause serious side effects. See "What is the most important information I should know about TAZVERIK?"

The most common side effects of TAZVERIK in people with epithelioid sarcoma include:

  • pain
  • nausea
  • vomiting
  • tiredness
  • decreased appetite
  • constipation

The most common side effects of TAZVERIK in people with follicular lymphoma include:

  • tiredness
  • bone and muscle pain
  • cold-like symptoms (upper respiratory infection)
  • nausea
  • stomach (abdominal) pain

These are not all the possible side effects of TAZVERIK.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store TAZVERIK?

Do not store TAZVERIK tablets above 86°F (30°C).

Keep TAZVERIK and all medicines out of the reach of children.

General information about the safe and effective use of TAZVERIK.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TAZVERIK for a condition for which it was not prescribed. Do not give TAZVERIK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAZVERIK that is written for health professionals.

What are the ingredients in TAZVERIK?

Active Ingredient: tazemetostat.

Inactive Ingredients: Tablet core: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, and sodium starch glycolate. Film-coating: hypromellose, polyethylene glycol, red iron oxide, talc, and titanium dioxide.

Manufactured for: Epizyme, Inc.

An Ipsen Company

One Main St.

Cambridge, MA 02142 For more information, contact Epizyme at 855-463-5127.

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 211723 · View the label on DailyMed

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Tazverik

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Methyltransferase Inhibitor
Active ingredient Tazemetostat hydrobromide 200 mg
Dosage form Tablet, film coated
Route Oral
Marketing status listed in the FDA NDC Directory
Company (applicant) EPIZYME INC
FDA approval NDA 211723New Drug Application (NDA) Approved January 23, 2020
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Drug shortage
  • Being discontinued since March 27, 2026
Packages (NDC)
Package
200 mg – 240 in 1 bottle NDC 72607-100-00

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.